Genprex Reports Positive Preclinical Data on Reqorsa Gene Therapy; Regains Nasdaq Compliance

MT Newswires Live11-06

Genprex (GNPX) said Tuesday that its lead drug candidate Reqorsa demonstrated positive results in a preclinical study in mice.

In one mice group that was supplemented with the Reqorsa gene therapy, Genprex said tumor growth was diminished and there was a "significant reduction in T reg" as well as a "significant increase in Cytotoxic T cells." Compared to the control group, the mice supplemented with Reqorsa also demonstrated a "significant increase in Granzyme B expression within Cytotoxic T cells and NK cells."

Separately, the company said it received a letter from Nasdaq's Listing Qualifications Department on Monday stating it regained compliance with the minimum bid price requirement.

Shares were down almost 11% in recent trading.

Price: 1.80, Change: -0.22, Percent Change: -10.89

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment